Last reviewed · How we verify
Ropivacaine 0.2% for S-ESPB
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Regional anesthesia via serratus anterior plane block (S-ESPB) for chest wall procedures and pain management.
At a glance
| Generic name | Ropivacaine 0.2% for S-ESPB |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and action potential generation in sensory and motor nerves. When administered via serratus anterior plane block (S-ESPB), it provides regional anesthesia to the chest wall and surrounding structures.
Approved indications
- Regional anesthesia via serratus anterior plane block (S-ESPB) for chest wall procedures and pain management
Common side effects
- Systemic toxicity (CNS effects: dizziness, tinnitus, seizures)
- Cardiovascular effects (hypotension, bradycardia, arrhythmias)
- Local tissue irritation or injection site reactions
- Allergic reactions
Key clinical trials
- PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery (NA)
- ACB With S-ESPB Versus ACB With iPACK for Knee Arthroplasty (NA)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
- PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.2% for S-ESPB CI brief — competitive landscape report
- Ropivacaine 0.2% for S-ESPB updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI